Ready4bluesky,
Your handle says it all. I think we are all ready. My hint does constitute a part of the risk/reward÷time ratio so I will take up your query.
Biotech investing generally is best suited for traders that work the shorter term cycles. Those who do invest in this sector absolutely need to be honest with themselves about risk over time tolerance. If this is what you want me to agree with you about I do. What I don't agree about is the need to avoid the risk and potential reward involved with any small cap entirely just because a company has an unsettling management style or strategy. As for those who have held for a while, last year was a good year to mitigate risk near the high. For those who have held like me, we still see reason to wait and one of those reasons is all about CXCR4.
For now, NWBO is priced almost at failure valuation for L as the current situation they face with an ongoing investigation and regulator review of data necessitates restraint by Mr. Woodford and others. Retail has now had the opportunity to purchase at nearly 90% off the 52 week high. Failure of DCVax-L would take the price under $1 for a while anyway but this Phase 3 does not look like it will be a total failure. In all likelihood the trial will be allowed to finish enrollment as a minimum and HE reimbursement would follow. What is going on now with regulators seems to be separate from the opportunity with HE. In the mean time we might want to look at clues as to why Mr. Woodford likes the science. Care to share what you know about the importance of CXCR4?
News 
Market Data 
Discover 
